Company Overview - Humana Inc. (HUM) is headquartered in Louisville, Kentucky, and provides medical and specialty insurance products with a market cap of $21.6 billion [1] - The company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products [1] Market Position - HUM is classified as a large-cap stock, underscoring its size, influence, and dominance within the healthcare plans industry [2] - The company leads the Medicare Advantage sector with a substantial customer base and competitive edge, driven by a focused strategy [2] - Humana has diversified into healthcare services, including primary care and pharmacy benefit management, capturing more value in the healthcare chain [2] Stock Performance - HUM has experienced a significant decline, slipping 43.2% from its 52-week high of $315.35, achieved on September 5, 2025 [3] - Over the past three months, HUM stock declined 30.5%, underperforming the S&P 500 Index's 1.9% decline during the same period [3] - Year-to-date, shares of HUM fell 30.1% and dipped 32.6% over the past 52 weeks, notably underperforming the S&P 500's YTD 1.5% losses and 17.5% returns over the last year [3] Technical Indicators - HUM has been trading below its 50-day and 200-day moving averages since late January, confirming a bearish trend [4] Financial Results - In Q4, HUM reported an adjusted loss of $3.96 per share, which beat Wall Street expectations of $4.01 per share [5] - The company's adjusted revenue was $32.6 billion, surpassing Wall Street forecasts of $31.9 billion [5] - HUM expects full-year adjusted EPS to be $9 [5] Competitive Landscape - The Cigna Group (CI) has taken the lead over HUM in the competitive healthcare plans arena, showing resilience with a 1.3% loss on a YTD basis [6] - Wall Street analysts maintain a consensus "Moderate Buy" rating for HUM, with a mean price target of $219.13, suggesting a potential upside of 22.3% from current price levels [6]

Company Overview - UnitedHealth Group Incorporated (UNH) is headquartered in Minnetonka, Minnesota, and has a market cap of $255.8 billion, providing health systems management and employee benefit program resources globally [1][2]. Market Position - UNH is classified as a "mega-cap stock" due to its market cap exceeding $200 billion, indicating its significant size and influence in the healthcare plans industry [2]. Stock Performance - UNH shares have experienced a decline of 53.4% from their 52-week high of $606.36, reached on April 11, 2025, and have fallen 14.5% year-to-date (YTD) and 38.8% over the past 52 weeks [3][5]. - The stock has been trading below its 50-day and 200-day moving averages, confirming a bearish trend [5]. Financial Results - In Q4, UNH reported an adjusted EPS of $2.11, slightly beating Wall Street expectations of $2.09, but its revenue of $113.2 billion fell short of forecasts of $113.3 billion [8]. Challenges - The company faces challenges such as higher medical costs impacting insurance margins, particularly in Medicare Advantage, and a projected decline in Medicare Advantage enrollments by 1.3 to 1.4 million members in 2026, along with Medicaid funding cuts [7]. Analyst Sentiment - Wall Street analysts maintain a "Moderate Buy" rating for UNH, with a consensus mean price target of $361.43, suggesting a potential upside of 28% from current price levels [9].

Molina Healthcare MOH analysishttps://t.co/zKuUiU8bhp https://t.co/e88ZsgVJ5g ...

Core Insights - Centene Corporation (CNC) is expected to report a fourth-quarter 2025 loss of $1.25 per share on revenues of $48.24 billion, indicating a significant year-over-year earnings decline of 256.3% despite revenue growth of 18.2% [1][2] Financial Performance - The Zacks Consensus Estimate for Centene's total revenues in 2025 is $192.12 billion, reflecting a year-over-year increase of 17.8%, while the EPS estimate for 2025 is $2.01, indicating a 72% decrease year-over-year [3] - Centene has beaten earnings estimates in three of the last four quarters, with an average surprise of 75.2% [3] Earnings Predictions - The current model does not predict an earnings beat for Centene, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [4] Membership and Premiums - Centene's premiums are projected to rise by 22.5% year-over-year, driven by gains in commercial membership, although total membership is expected to decline by 2.4% [7][9] - The Zacks Consensus Estimate indicates a 29.7% year-over-year increase in total commercial memberships and a 15.6% growth in Medicare PDP memberships [8] Cost and Margin Pressures - The total health benefits ratio is estimated to be 93.7%, up from 89.6% in the previous year, indicating increased medical costs that are expected to pressure earnings [10] Industry Comparisons - UnitedHealth Group reported a fourth-quarter adjusted EPS of $2.11, beating estimates but showing a 69% year-over-year decline due to elevated medical costs [11] - Elevance Health reported an adjusted EPS of $3.33, surpassing estimates and showing a 3.1% year-over-year increase, although it faced challenges from declining overall medical membership [12]

Core Insights - Molina Healthcare, Inc. (MOH) is scheduled to report its fourth-quarter 2025 results on February 5, 2026, with earnings estimated at 43 cents per share and revenues at $10.8 billion [1][7]. Financial Performance - The fourth-quarter earnings estimate has remained stable over the past 60 days, indicating a year-over-year decrease of 91.5%, while revenues are projected to grow by 2.9% year over year [2]. - For the full year 2025, the revenue estimate stands at $44.89 billion, reflecting a 10.4% increase year over year, but the earnings per share estimate is $13.99, showing a decline of 38.23% year over year [3]. Membership and Premiums - Molina Healthcare expects to gain Medicare membership, while Medicaid membership is projected to decline by 6.4% year over year [7]. - The Zacks Consensus Estimate for premiums indicates a growth of 2.4% year over year in the fourth quarter, with Medicare premiums estimated at $1.4 billion, up 4.9% year over year [10]. Medical Care Ratio (MCR) and Costs - The consensus mark for the medical care ratio (MCR) in the marketplace is pegged at 94.8%, up from 83.3% a year ago, and the total MCR is expected to be around 93%, up from 90.2% [12]. - Rising costs and lower investment income contribute to uncertainty regarding earnings performance, with a projected 9.8% decline in investment income and a 6.1% increase in total operating expenses due to higher medical care costs and general administrative expenses [13]. Industry Context - Major peers such as UnitedHealth Group and Elevance Health have reported their fourth-quarter results, with UnitedHealth showing a 12% year-over-year revenue increase to $113.2 billion despite a 69% decline in adjusted earnings per share due to elevated medical costs [15]. - Elevance Health reported adjusted EPS of $3.33, surpassing estimates by 7.3%, driven by strong premium growth, although overall medical membership declined [16]. - The Cigna Group is projected to have an 18.5% year-over-year increase in earnings for the fourth quarter, with a 6.5% growth in revenues [17].

UnitedHealth Takes $1.6 Billion Hit To Earnings Amid Restructuring https://t.co/0fpaotgtIz ...

UnitedHealth Group reported fourth-quarter results and issued 2026 earnings guidance that were in line with lowered Wall Street expectations, as the company said it was making progress on its financial turnaround https://t.co/012vSwo896 ...

UnitedHealth is forecasting its first revenue decline in more than 30 years. Now its peers are sliding too, after the Trump administration proposed to keep private Medicare payments flat. Bloomberg’s Ike Swetlitz joined Bloomberg Open Interest to talk about what it means for insurers—and patients. -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.b ...

RT Watcher.Guru (@WatcherGuru)Last month, Rep. Kevin Hern sold up to $500,000 worth of UnitedHealth stock.Today, the Trump administration proposed flat Medicare reimbursement rates for insurers, causing $UNH to crash over 10%.Hern is a member of the House Subcommittee on Health. https://t.co/fZBPjriGkR ...

RT Watcher.Guru (@WatcherGuru)Last month, Rep. Kevin Hern sold up to $500,000 worth of UnitedHealth stock.Today, the Trump administration proposed flat Medicare reimbursement rates for insurers, causing $UNH to crash over 10%.Hern is a member of the House Subcommittee on Health. https://t.co/fZBPjriGkR ...